Obstructive Sleep Apnea Affects Up to 18 Million Patients In the US With as Many...

* Reuters is not responsible for the content in this press release.

Tue Apr 15, 2008 10:32am EDT 

Obstructive Sleep Apnea Affects Up to 18 Million Patients In the US With as Many as 85% Are Undiagnosed

DUBLIN, Ireland--(Business Wire)--
Research and Markets
(http://www.researchandmarkets.com/reports/c88855) has announced the
addition of "Undiagnosed Sleep Disorder Market Offers Growth
Opportunities" to their offering.

   There are more than 70 different sleep disorders but the most
common ones include insomnia, sleep apnea, restless legs syndrome, and
narcolepsy. One of the fastest growing sector in the sleep disorder
treatment market is obstructive sleep apnea (OSA) products. OSA
affects up to 18 million patients in the US with as many as 85% are
undiagnosed.

   Similarly, 30 million are chronic sufferers of insomnia but only a
third of chronic sufferers are receiving treatment. A key reason for
this low percentage of people receiving treatment is the side effects
associated with most of the insomnia drugs. Over 1.6 million Americans
use some form of alternative medicine to treat insomnia.

   With rising awareness of sleep disorders, more people are
undergoing tests to understand the basics of their sleep disorder
condition. Hospitals are opening new sleep centres and upgrading old
ones. Patients are looking at innovative aspects in sleep centres
which make them feel more homely.

   Pharma companies are coming up with new sleeping disorder drugs.
Gamma Aminobutyric Acid (GABA) agents dominate the insomnia market.
More than a dozen insomnia drugs are in phase II and phase III
clinical trials. Major products are Ambien, Ambien CR, Lunesta,
Temazepam, and Zolpidem. Respironics and ResMed are the leading
competitors in the continuous positive airway pressure (CPAP) market.

   The report analyzes the sleep disorder treatment market. The focus
is on OSA and insomnia treatment products. The report also profiles
the major companies, with a discussion of their key business
strategies. It also analyzes the major market and demographic trends
prevalent in the sleep disorder treatment market.

   Key Discussions:

   - Sleep Disorders: An Introduction

   - Market Overview

   - Market Trends

   - Demographic Trends

   - Competitive Landscape

   - Company Profiles

   Companies mentioned:

   - Respironics

   - ResMed

   - Neurocrine

   - Neurogen

   For more information visit
http://www.researchandmarkets.com/reports/c88855.

Research and Markets
Laura Wood
Senior Manager
Fax: +353 1 4100 980
press@researchandmarkets.com

Copyright Business Wire 2008
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.